Pharvaris Announces Annual General Meeting of Shareholders

(Very High)

(Neutral)

Rhea-AI Summary

Pharvaris (Nasdaq: PHVS) announced its annual general meeting of shareholders will be held on Friday, June 26, 2026, at 16:00 CEST (10:00 a.m. EDT).

Meeting documents, including the notice and agenda, are available in the website’s Investors > Events & Presentations section and on the SEC website.

News Market Reaction – PHVS

+2.19%

+2.19% Session close to close

In the Jun 11 session, PHVS gained 2.19%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement sets the timing and logistics for Pharvaris’ annual general meeting on June 26, 20...

Analysis

This announcement sets the timing and logistics for Pharvaris’ annual general meeting on June 26, 2026 at 16:00 CEST (10:00 a.m. EDT). It follows a period of active clinical communication and capital raising, including recent HAE trial updates and two sizable equity offerings. Investors may focus more on upcoming Phase 3 readouts and regulatory milestones than on this procedural event, while also monitoring governance signals and continued execution on the HAE strategy.

Key Figures

AGM date: June 26, 2026 AGM time CEST: 16:00 CEST AGM time EDT: 10:00 a.m. EDT

3 metrics

AGM date June 26, 2026 Scheduled date of annual general meeting

AGM time CEST 16:00 CEST Local time of annual general meeting

AGM time EDT 10:00 a.m. EDT US Eastern time of annual general meeting

Historical Context

5 past events · Latest: May 29 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
May 29	Clinical data plans	Positive	+1.0%	Announcement of multiple Phase 2/3 deucrictibant data presentations at EAACI 2026.
May 12	Earnings & pipeline	Positive	+5.4%	Q1 2026 update with €247M cash, added $132.3M raise, and clear HAE timelines.
May 11	Equity offering close	Negative	+4.3%	Closing of $132.3M underwritten offering of 4,455,863 ordinary shares.
May 08	Equity offering price	Negative	+1.4%	Pricing of $115M share offering at $29.68 per share with 30-day option.
Apr 20	Clinical data update	Positive	+1.4%	Conference data on combined deucrictibant IR/XR use showing supportive safety margins.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Over recent months PHVS has often shown positive price reactions to both clinical updates and capital-raising offerings, suggesting constructive sentiment toward its HAE pipeline and funding moves.

Recent Company History

In the last few months, Pharvaris reported several notable milestones. On Apr 20, 2026, it presented data supporting combined deucrictibant IR/XR use in HAE. Two May offerings, including a $115 million underwritten deal at $29.68 per share and a later $132.3 million offering of 4,455,863 shares, both saw positive price reactions. First-quarter 2026 results on May 12 highlighted €247 million in cash and an additional $132.3 million raise, alongside clear timelines for Phase 3 readouts and an NDA filing. The latest EAACI clinical data announcement on May 29 also coincided with a modest gain. Against this backdrop, today’s AGM notice fits as routine corporate housekeeping.

Key Terms

bradykinin b2 receptor antagonists, hereditary angioedema, acquired angioedema, c1 inhibitor deficiency

4 terms

bradykinin b2 receptor antagonists medical

"developing novel, oral bradykinin B2 receptor antagonists to help address"

Bradykinin B2 receptor antagonists are drugs that block a specific cell receptor which responds to bradykinin, a natural molecule that causes blood vessels to leak, swell and send pain signals; blocking that receptor can reduce swelling, pain and inflammation. For investors, these drugs matter because successful candidates can address acute or chronic conditions with high unmet need, and their clinical trial results, safety profile and regulatory approvals strongly influence a company’s market value—think of the drug as putting a cap on a leaking pipe to stop costly damage.

hereditary angioedema medical

"bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired"

A rare inherited disorder that causes sudden, painful swelling under the skin or in internal tissues, including the airway, because a natural blood‑control protein is missing or not working. Attacks can be unpredictable and sometimes life‑threatening, so people often need ongoing medication or emergency treatment. For investors, hereditary angioedema represents a niche but stable market for specialized therapies, diagnostics, and emergency care solutions.

acquired angioedema medical

"hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor"

Acquired angioedema is a rare condition where the immune system causes sudden swelling of the skin and tissues—often around the face, throat or limbs—because a protein that normally controls fluid leakage is deficient or blocked. For investors, it matters because its rarity, potential severity and unmet treatment needs drive demand for diagnostics, specialist drugs and hospital care, creating focused market opportunities and regulatory attention similar to niche product markets.

c1 inhibitor deficiency medical

"acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today"

A deficiency of the C1 inhibitor is a medical condition where a key protein that acts like a brake on parts of the immune and inflammation system is missing or not working, causing sudden, sometimes severe episodes of painless or painful swelling in tissues including the skin, gut and airway. It matters to investors because the condition defines markets for specialized diagnostics, long‑term therapies and emergency treatments; changes in approved treatments, pricing or reimbursement can materially affect companies developing drugs, devices or tests for it.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

06/11/2026 - 06:50 AM

ZUG, Switzerland, June 11, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the annual general meeting of shareholders will take place on Friday, June 26, 2026, at 16:00 CEST (10:00 a.m. EDT).

All relevant documents and information relating to the annual general meeting, including the notice and agenda for the annual general meeting, are or will be made available in the “Investors” section of Pharvaris’ website under “Events & Presentations”. The documents will also be made available on the SEC’s website at www.sec.gov. Shareholders who wish to attend the meeting should register as described in the notice and agenda for the annual general meeting.

About Pharvaris
Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs in bradykinin-mediated conditions, including all types of bradykinin-mediated angioedema. Pharvaris’ aspiration is to offer therapies with injectable-like efficacy™, a well-tolerated profile, and the convenience of oral administration to prevent and treat bradykinin-mediated angioedema attacks. By delivering on this aspiration, Pharvaris aims to provide a new standard of care in bradykinin-mediated angioedema. Pharvaris is preparing marketing authorization applications for deucrictibant immediate-release capsule as an on-demand treatment of HAE attacks, and a global pivotal Phase 3 study of deucrictibant extended-release tablet for the prevention of HAE attacks (CHAPTER-3) is ongoing with topline data anticipated in the third quarter of 2026. In addition, CREAATE is an ongoing Phase 3 study of deucrictibant for the prophylactic and on-demand treatment of AAE-C1INH attacks. For more information, visit https://pharvaris.com/.

Contact
Maggie Beller
Vice President, Head of Corporate and Investor Communications
maggie.beller@pharvaris.com

FAQ

When is the 2026 annual general meeting of Pharvaris (PHVS) shareholders?

The 2026 annual general meeting of Pharvaris shareholders is scheduled for Friday, June 26, 2026. According to Pharvaris, the meeting will take place at 16:00 CEST, which corresponds to 10:00 a.m. EDT for U.S.-based shareholders.

What time does the Pharvaris (PHVS) 2026 annual general meeting start in CEST and EDT?

The Pharvaris 2026 annual general meeting starts at 16:00 CEST, or 10:00 a.m. EDT. According to Pharvaris, shareholders should check the official notice and agenda for detailed attendance instructions and any additional timing or access information.

Where can Pharvaris (PHVS) investors find the agenda and notice for the June 26, 2026 AGM?

Investors can find the AGM notice and agenda in the Investors section of the Pharvaris website. According to Pharvaris, these documents appear under “Events & Presentations” and will also be made available on the SEC’s website at www.sec.gov.

How can Pharvaris (PHVS) shareholders register to attend the 2026 annual general meeting?

Shareholders must register for the Pharvaris 2026 annual general meeting as described in the official notice and agenda. According to Pharvaris, all relevant instructions are included in the AGM materials available online to ensure proper shareholder registration and participation.

Where will Pharvaris (PHVS) publish documents for the 2026 shareholders’ meeting?

Pharvaris will publish AGM documents in the Investors section of its website and on the SEC site. According to Pharvaris, materials such as the notice, agenda, and related information are or will be accessible under “Events & Presentations.”